COVID-19 vaccine and treatment sales helped Pfizer breeze past Wall Street's first-quarter expectations, as the drugmaker's profit grew 61%.
All that helped company revenue swell 77%, compared to last year's quarter, when vaccine sales were still ramping up. Pfizer books the vast majority of revenue from Comirnaty and splits profit, as well as the cost to make and distribute the vaccine, with development partner BioNTech. “We are seeing strong signs for increasing demand for Paxlovid,” Chairman and CEO Albert Bourla told analysts Tuesday.
During a Tuesday conference call to discuss the quarter, another analyst asked Pfizer executives about reports of COVID-19 recurring in patients after they have completed a Paxlovid treatment course.
Why is there no talk about the negative effects these pills are having on people , the production of these pill according to the , Nuremberg code should be stopped immediately but , they keep pushing them on people .
Well, isn't that special. Huh.....who would have thought......
Paying the devil his dues
-Taxpayer funded vaccines -Patents not shared for third world countries production -Pushing through for 6mo-5yo with no significant effective data -Didn’t do what it said on the tin -didn’t want to release research for 75 years Yeeeah, Seems legit Pfizer 👍
Gawd damn! 🤑
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WSJhealth - 🏆 413. / 53 Read more »
Source: nypost - 🏆 91. / 67 Read more »
Source: FoxBusiness - 🏆 458. / 53 Read more »
Source: CNBC - 🏆 12. / 72 Read more »
Source: MarketWatch - 🏆 3. / 97 Read more »
Source: njdotcom - 🏆 282. / 63 Read more »